Previous 10 | Next 10 |
Humanigen (NASDAQ: HGEN) stock is sinking after the clinical-stage biopharmaceutical company shared devastating news. The FDA has declined Humanigen's request for emergency use authorization of lenzilumab, sending the biotech stock 52.1% lower as of 11:38 a.m. EDT on Thursday. ...
Gainers: ProQR Therapeutics (NASDAQ:PRQR) +22%, Centessa Pharmaceuticals CNTA +22%, Kiromic BioPharma (NASDAQ:KRBP) +19%, Trinity Biotech TRIB +16%, Enveric Biosciences (NASDAQ:ENVB) +14%. Losers: Humanigen HGEN -54%, Invacare IVC -34%,...
JP Morgan has cut Humanigen (HGEN -49.0%) to underweight from neutral and is withdrawing its price target after the FDA declined the company's request for an Emergency Use Authorization for lenzilumab for hospitalized COVID-19 patients. Analyst Eric Joseph said he wasn't that surprised with t...
Humanigen (NASDAQ:HGEN) -59% after FDA declined emergency use approval of lenzilumab in COVID-19 Certara (NASDAQ:CERT) -8% after prices equity offering at $31 GameStop (NYSE:GME) -8% on Q2 earnings release DouYu International (NASDAQ:DOYU) -7%. Mechel (NYSE:MTL) ...
FDA has committed to working with Humanigen in the development of lenzilumab and has invited Humanigen to submit additional data as it becomes available NIH’s ACTIV-5/BET-B study is expected to provide further data that may support a new EUA request Humanigen remains co...
As the rapid spread of the COVID-19 Delta variant continues to disrupt several economies, there is growing concern about the virus’ potential long-term physical effects. Given this backdrop, which suggests more therapies will need to be developed, we think it could be wise to investiga...
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm’” with its lead drug candidate, lenzilumab, today provided a corporate and regul...
Lenzilumab treatment in Black and African-American patients in the positive LIVE-AIR Phase 3 trial, having a CRP<150 mg/L, resulted in a nearly 9-fold increase in survival without ventilation CDC data shows Black and African-American persons are at an almost 3-fold greater risk...
ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR study Primary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/L Study modification may en...
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug ab...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...